Pl 7000

Manufactured by Pro-Lab Diagnostics

The PL.7000 is a multi-functional diagnostic laboratory instrument designed for clinical analysis. It is capable of performing various tests and assays to support patient healthcare. The PL.7000 leverages advanced technology to deliver accurate and reliable results, but a detailed description of its specific capabilities is not available at this time.

Automatically generated - may contain errors

Lab products found in correlation

Colcount system, by Oxford Optronix (3 mentions) Tryple express 1, by Thermo Fisher Scientific (1 mentions) Mccoy s 5a, by Thermo Fisher Scientific (1 mentions) Tryple express, by Thermo Fisher Scientific (1 mentions) Fetal bovine serum (fbs), by Thermo Fisher Scientific (1 mentions) Tryple express 1x, by Thermo Fisher Scientific (1 mentions) L glutamine, by Thermo Fisher Scientific (1 mentions)

3 protocols using pl 7000

Clonogenic Assay with HT29-Luc2 CRC Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 17

HT29-Luc2 CRC cells were maintained using McCoy's 5A (Gibco 36600-088) medium supplemented with 10% FBS (Gibco 10270-106) at 37° C./5% CO2. Cells were washed in DPBS and trypsinised using 2 ml TrypLE™ Express (1×) (Invitrogen). Cells were centrifuged following detachment at 1200 rpm for 4 minutes. The cell pellet was resuspended in full media and a cell count was performed using a haemocytometer. 1.5×10³cells were seeded per well of a 6 well plate and left to adhere for 24 hours. Cells were then treated with 10 μM of compound 4 or 18 for 24 hours. The drugs were then removed and cells were allowed to grow in fresh media for 10 days in total, clones were then fixed using 4% paraformaldehyde and stained by incubating with 0.5% crystal violet solution (Pro-Lab diagnostics PL.7000) at RT for 2 hours. Clones counting was performed using the ColCount™ system (Oxford Optronix).

US09975860B2. Anti-angiogenic compounds (2018-05-22). UNIVERSITY COLLEGE DUBLIN—NATIONAL UNIVERSITY OF IRELAND, DUBLIN [IE], THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN [IE]. Inventors: Breandan Kennedy [IE], Alison Reynolds [IE], Jacintha O'Sullivan [IE], Andrew Douglas Baxter [GB].

+ Open protocol

+ Expand

Clonogenic assay of colorectal cancer cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

HT29-Luc2 CRC cells were maintained in McCoy’s 5A (Gibco) medium supplemented with 10% FBS (Gibco) at 37°C/5% CO₂. Cells were washed in DPBS and trypsinised using 2 ml TrypLE™ Express (Gibco). Cells were centrifuged following detachment at 1,200 rpm for 4 minutes. Cell pellets were re-suspended in full medium and a cell count was performed using a haemocytometer. 1.5 × 10³ cells were seeded per well of a 6-well plate and left to adhere for 24 hours. Cells were then treated with 10 μM or 20 μM of quininib (Q1), Q8, Q18, Q22, P4 or P18 for 24, 48, 72 and 96 hours. The drugs were removed and cells were grown in fresh media for 10 days in total, clones were then fixed using 4% paraformaldehyde and stained by incubating with 0.5% crystal violet solution (Pro-Lab diagnostics PL7000) at RT for 2 hours. Clone counting was performed using the ColCount™ system (Oxford Optronix).

Butler C.T., Kennedy S.A., Buckley A., Doyle R., Conroy E., Gallagher W.M., O’Sullivan J, & Kennedy B.N. (2019). 1,4-dihydroxy quininib attenuates growth of colorectal cancer cells and xenografts and regulates the TIE-2 signaling pathway in patient tumours. Oncotarget, 10(38), 3725-3744.

+ Open protocol

+ Expand

Clonogenic Assay for HT-29-luc2 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

The HT-29-luc2 Bioware^® Ultra cell line was purchased from PerkinElmer (UK) and maintained in McCoy’s 5A media with L-glutamine (Fisher) supplemented with 10% fetal calf serum. Cells were washed in DPBS and trypsinised using 2 ml TrypLE Express (1X) (Invitrogen). 1.5 × 10³ cells were seeded per well of a 6 well plate and incubated for 24 hours. Cells were then treated with 10 or 20 μM of quininib, 5-fluorouracil (5FU) or 0.1% DMSO vehicle for 24, 48, 72 and 96 hours. The drugs were removed and cells were allowed to grow in fresh media for 10 days in total. Clones were then fixed using 4% paraformaldehyde and stained with 0.5% crystal violet solution (Pro-Lab diagnostics PL.7000) at RT for 2 hours. Clone counting was performed using the ColCount system (Oxford Optronix).

Murphy A.G., Casey R., Maguire A., Tosetto M., Butler C.T., Conroy E., Reynolds A.L., Sheahan K., O’Donoghue D., Gallagher W.M., Fennelly D., Kennedy B.N, & O’Sullivan J. (2016). Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer. Scientific Reports, 6, 34523.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!